Cell Contamination: Relevance to Radiation Experiments

I would like to respond to William J. Broad's article "The case of the unmentioned malignancy" (News and Comment, 12 Dec. 1980, p. 1229). I worked for and with Paul Todd from 1969 to 1978 and was responsible for much of the tissue culture operation in the laboratory during that time. I feel a disparaging shadow has been unjustly cast over Todd's professional reputation by Broad's article.

The following points should be noted. 1) Furcinitti and Todd (1) measured cell death at low gamma ray doses, not genetic mutations or transformation from the "normal" to the "cancerous" state. Broad's reference to the New Scientist headline (2) that "Low radiation doses do cause cancer" is that magazine's premature conclusion. Furcinitti and Todd never made that statement in their report; they merely suggested that their findings "should stimulate a more intense experimental investigation of the applicability of the linear hypothesis to human mutagenesis and carcinogenesis" (1). They regretted the New Scientist's misleading statements in Science (3), a fact not mentioned in Broad's article.

2) Our laboratory always operated under the premise that "normal" (for cultured mammalian cells) meant that they were diploid and had a finite capacity for cell multiplication (4). T-1 cells have been passaged hundreds of times and were known to be very heteroploid (5-7). Even if T-1 had been derived from normal tissue, only the most naïve tissue culturist would feel they were representative of "normal" tissue.

3) With regard to the credibility of the data obtained with T-1, it is important radiobiologically to use one cell line so that nuclear cross-sectional areas, repair capacities, and so forth are fairly consistent from experiment to experiment and from laboratory to laboratory. T-1 cells fill that need. Nelson-Rees et al. have shown that the various T-1 lines throughout the world are karyotypically similar with a "likelihood of a clonal derivation of all T-1 cultures'' (8). The use of an established line of cells technically and financially facilitates radiobiological research in its early stages. The use of "normal" diploid fibroblasts like WI-38 would require significantly larger expenditures for dishes, serum, media, and labor and thereby restrict the amount of data obtained.

What do data obtained with T-1 cells have to do with the real world? Probably no less than if the same data were obtained with any other cell line. We showed how similar cell lines can vary radiobiologically under similar conditions (6), and Nelson-Rees and Flandermeyer state that "It is, no doubt true that the different bona fide strains of HeLa perform in different ways and exhibit many distinct characteristics; the same is true of cultures of HeLa that are known by different designations, but are de facto HeLa strains themselves" (9).

Had "normal" WI-38 been the cell line of choice among radiobiologists, the low plating efficiency, technical demands, and the progressive senescence of the cell line would add almost as many complications to data interpretation and extrapolation as we have now with T-1 cells. It is a very long jump from logphase, partially or fully dedifferentiated cells in a dish to the mostly stationaryphase and differentiated cells in a human body. It is even risky to assume that what is true for cell line A is also true for cell line B, as the quote above (9) states.

4) Our first knowledge of the possible HeLa origin of T-1 cells came when I submitted a sample to the American Type Culture Collection (ATCC) with the hope that it might be an established human cell line of epithelial-like morphology that was not suspected of being HeLa contaminated. Several, if not all, of the ATCC holdings in that category at that time had HeLa markers (10). I was informed that the ATCC found the isozyme G6PD(A), one copy of HeLa marker chromosome No. 2, and two copies each of No. 3 and No. 4 (7, 11). With the ubiquity of HeLa markers in the ATCC lines, we could not exclude the possibilities of an assay artifact or the inadvertent finding that many established human lines develop these markers. As we never considered T-1 "normal" in any way and none of our data was immediately affected, we did not pursue it further. I openly described the foregoing to the point of stating that "it appears likely that our T-1 cells are HeLa cells" (7). Todd tried in vain to publish the findings, uncertain as they were, and this is mentioned in Broad's article. There was never any cover-up.

5) Nelson-Rees et al. state that "If a human cell, whether normal or tumor, sufficed in the protocol, the conclusions drawn remain sound" (8). T-1 cells are as good as any other established cell line for the colony-formation experiments in question. The conclusions drawn by Furcinitti and Todd (1, 3) are considerably more conservative than the headline in the New Scientist (2) and Broad's article might lead one to believe.

CARTER B. SCHROY

Department of Radiology, Division of Radiation Biology. Case Western Reserve University, Cleveland, Ohio 44106

References

- 1. P. S. Furcinitti and P. Todd, Science 206, 475 (1979).
- New Sci. 84, 439 (1979).
 P. S. Furcinitti and P. Todd, Science 210, 806
- (1980).
 L. Hayflick and P. S. Moorhead, Exp. Cell Res.
- L. Haymer and F. S. Moonwad, *Exp. Cent. Res.* 25, 585 (1961).
 P. W. Todd, *Univ. Calif. Radiat. Lab. Rep.* UCRL-11614 (1964).
 C. B. Schroy and P. Todd, *Mutat. Res.* 33, 347 (1975).
- (1975)7. C. B. Schroy, thesis, Pennsylvania State Uni-
- 8.
- W. A. Nelson-Rees, R. R. Flandermeyer, D. W. Daniels, Science 209, 720 (1980).
 W. A. Nelson-Rees and R. R. Flandermeyer, *ibid.* 191, 96 (1976).
 S. Grieneda, Network (London) 250, 170 (1060). 9.
- 101. 191, 90 (1976);
 10. S. Grimwade, *Nature (London)* 259, 172 (1976);
 K. S. Lavappa *et al.*, *ibid.*, p. 211.
 11. R. J. Hay, personal communication.

Creationism in Toronto

In a recent summary of the Toronto AAAS meeting (News and Comment, 23 Jan., p. 368), Nicholas Wade faulted the session "Views of the Universe: Science versus Tradition'' for not including "creationists" as speakers. In doing so, he missed an important point that was made in several contexts during the session.

We considered including a defender of a specific "creationist" point of view, and immediately ran up against the question of which such point of view to include. Some people believe firmly the universe was created in the recent past, others in the remote past, and yet others that there was never a specific creation ("steady-state" or "cyclic" cosmologies); there is similarly a wide (and mutually exclusive) variety of accounts of the beginnings of mankind (1). It was impractical to include representatives of each, and yet no defender of one would defend any other. Thus, one of the speakers (Milton K. Munitz) addressed the nature of a number of creation traditions.

Another speaker (William V. Maver) discussed at length one particular "creationist movement" active in the United States and Canada. This is the one referred to by Wade as though it were the only such movement differing with the corpus of science. But the discoveries of science have conflicted with tradition along a number of lines, both today and in the past, in different cultures. The



Advanced Technology

Edited by Philip H. Abelson and Mary Dorfman

Modern high technology rests on the skillful use of energy and materials, and of the two, for many applications. advanced materials are the most important. Leading industrial research laboratories are developing many new materials that will help solve our energy problems. The twenty articles in this Compendium present research on a wide range of topics in this field.

The contributors: B. C. Anderson, L. R. Bartron, J. W. Collette, T. Alfrey, Jr., W. Schrenk, J. Mort, L. L. Hench, P. Beardmore, J. J. Harwood, K. R. Kinsman, R. E. Robertson, R. N. Katz, B. H. Kear, E. R. Thompson, J. J. Gilman, M. S. Rashid, R. H. Wentorf, R. C. DeVries, F. P. Bundy, G. Y. Chin, J. K. Hulm, B. T. Matthias, A. W. Sleight, E. A. Perez-Albuerne, Y. -S. Tyan, J. M. Woodall, M. B. Panish, T.C. Penn, B. Kazan, E.A. Giess, C.I. Kircher, & M. Murakami.

168 pp. Illus. 1980 Cloth: ISBN 0-87168-303-2 \$14.00 Paper: ISBN 0-87168-249-4 \$6.00

A volume in the Science Compendia Series Order from AAAS/Dept. AT3, 1515 Massachusetts Avenue, NW, Washington, DC 20005 Orders under \$10 must be prepaid. AAAS members receive a 10% discount on prepaid orders. Please allow 6-8 weeks for delivery. For a complete listing of AAAS Science Compendia, write: AAAS Marketing Dept., 1776 Mass. Ave., NW, Washington, DC 20036.

problem we discussed in the session is only one example of a broad class. We did dwell upon this one example, but only because it threatens to compromise seriously science education in North America.

ROLF M. SINCLAIR

Section Committee, AAAS Section B (Physics), 1776 Massachusetts Avenue, NW, Washington, D.C. 20005

References and Notes

1. See, for example, B. C. Sproul, *Primal Myths:* Creating the World (Harper & Row, New York, 1979).

Culturing Before a Transplant

Thomas H. Maugh II, in his article on altering the donor organ (Research News, 10 Oct. 1980, p. 177), does not cite the work of Jacobs and of Lueker and Sharpton with cultured mouse ovarian allografts. These investigators found that a significant proportion of mouse ovaries that had been cultured for 6 to 12 days (Jacobs) or only 3 days (Lueker and Sharpton) were accepted when transplanted to major-locus incompatible recipients. Transplantation published these papers back-to-back (1), about 5 months before Lafferty's first report (2) appeared on the survival of cultured mouse thyroid allografts. In fact, we received Jacobs' paper about a month before the Lueker-Sharpton one, but with her permission, held her paper until the other one was reviewed so that we could publish them together. These papers represent the first reliable reports of the ability of short-term maintenance in vitro to promote the survival of allografts of normal tissue. Jacobs, working with Huseby, already had established this principle with tumor allografts as early as 1967 (3).

DAVID STEINMULLER Transplantation, c/o Department of Immunology, Mayo Clinic, Rochester, Minnesota 55901

References

- B. B. Jacobs, Transplantation 18, 454 (1974); D. C. Lueker and T. R. Sharpton, *ibid.*, p. 457.
 K. J. Lafferty, M. A. Cooley, J. Woolnough, K. Z. Walker, Science 188, 259 (1975).
 B. B. Jacobs and R. A. Huseby, Transplantation of the second sec tion 5, 410 (1967).

Erratum: The new chairman of the Senate Com-

Erratum: The new chairman of the Senate Com-mittee on Commerce, Science, and Transportation is Senator Bob Packwood (R-Ore.). Senator Harrison H. Schmitt (R-N.M.) was incorrectly identified as chairman (News and Comment, 6 Feb., p. 559). Erratum: Important information in the article "In-sulin wars: New advances may throw market into turbulence" (News and Comment, 12 Dec. 1980, p. 1225) came from a review written by Scott R. King of F. Eberstadt & Co., Inc., New York. Credit to King was inadvertently omitted from the article. King was inadvertently omitted from the article.